Phase 4 Completed N=349 Randomized Double-blind Treatment

Bupropion and Weight Control for Smoking Cessation - 1

Tobacco Use

Source: ClinicalTrials.gov NCT00006170 ↗

Enrolled (actual)

349

Serious AEs

0.0%

Results posted

Nov 2013

Primary outcomePrimary: Smoking Abstinence — 41; 18; 33; 19 percentage of participants — p=0.001

Summary

The purpose of this study is to determine whether the addition of bupropion (Zyban) to cognitive behavioral therapy (CBT) will enhance longer-term tobacco abstinence in women.

Outcome Measures

Outcome	Result	p-value
PRIMARY Smoking Abstinence	24; 8; 19; 7	0.006 sig
PRIMARY Smoking Abstinence	24; 8; 19; 7	0.006 sig
PRIMARY Smoking Abstinence	24; 8; 19; 7	0.006 sig

Eligibility Criteria

Inclusion Criteria

Smoke at least 10 cigarettes per day
Report concern about cessation-related weight gain
Motivated to quit smoking

Exclusion Criteria

Currently pregnant, lactating, or no medically approved method of contraception
Major medical problem
History of seizure disorder or head injury
Current or historical psychosis or bipolar disorder
History of alcohol or substance abuse within previous year
Current or historical eating disorder
Use of antidepressant medication, monoamine oxidase inhibitor or lithium with previous month
Multiple Drug Allergies
Current major depressive disorder

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00006170). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.